Items where contributor is "Lupatsch, Judith"

Group by: Date | Item Type | Refereed | No Grouping

Jump to: Yes

Yes

Bommer, Claudine and Lupatsch, Judith and Bürki, Nicole and Schwenkglenks, Matthias. (2021) Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. The European journal of health economics : HEPAC : health economics in prevention and care. DOI: 10.1007/s10198-021-01396-9.

Stoffel, Sandro Tiziano and von Moos, Roger and Thürlimann, Beat and Cathomas, Richard and Gillessen, Silke and Zürrer-Härdi, Ursina and von Briel, Thomas and Anchisi, Sandro and Feller, Anita and Schär, Corinne and Dietrich, Daniel and Schwenkglenks, Matthias and Lupatsch, Judith E. and Mark, Michael Thomas. (2021) Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study. Swiss medical weekly, 151. w20464.

Pillai, Nadia and Lupatsch, Judith E. and Dusheiko, Mark and Schwenkglenks, Matthias and Maillard, Michel and Sutherland, C. Simone and Pittet, Valérie E. H. and Swiss IBD Cohort study group, . (2019) Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data. Journal of Crohn's & colitis. jjz169.

Panje, Cedric M. and Dedes, Konstantin J. and Matter-Walstra, Klazien and Schwenkglenks, Matthias and Gautschi, Oliver and Siano, Marco and Aebersold, Daniel M. and Plasswilm, Ludwig and Lupatsch, Judith E.. (2018) A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 129. pp. 257-263.

Hirschmann, A. and Lupatsch, J. E. and Schwenkglenks, M. and Panje, C. M. and Matter-Walstra, K. and Espeli, V. and Dedes, K. J. and Siano, M.. (2018) Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral oncology, 87. pp. 104-110.